Avid Bioservices Inc (CDMO)

[Protector]

biopharm, for starters the IP period can be extended. An FDA hold is an officially accepted reason by the PTO to extend the protection if no activities under the protection have been executed. I think 7 extra years is the max, not sure.

Secondly in CAR-T I think BetaBodies, a more recent patent of second generation Bavi, full human, may be the preferred choice.

When blood is drawn one wants to extract the highest number of T-cells (the target) from as less blood as possible as quickly as possible and as pure as possible.

I think that clearing the blood may help in that and in that case targeting PtdSer is per betabodies and not bavituximab alike binding. remains to be verified.

AIMO